BTK Inhibitor Therapy: Delving Into Evolving Topics, Critical Aspects of Management, and Practice-Changing Data

Keep up to date with the latest developments in BTK inhibitor&ndash based therapy with this series of 3 expert commentaries focused on emerging clinical trial data toxicity management and patient adherence. Download the slideset based on the commentaries to use in your own presentations to colleagues and patients.

Share

Program Content

Activities

BTKi in B-Cell Malignancies
BTK Inhibitor Therapy: Delving Into Evolving Topics, Critical Aspects of Management, and Practice-Changing Data
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 29, 2020

Expires: May 28, 2021

Activities

BTKi in MCL/MZL
How I Use BTK Inhibitors to Treat Patients With MCL and MZL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 03, 2020

Expires: March 02, 2021

BTK Inhibitors in WM
How I Use BTK Inhibitors to Treat My Patients With Waldenström Macroglobulinemia
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 31, 2020

Expires: March 30, 2021

BTK Inhibitors for CLL
How I Use BTK Inhibitors to Treat My Patients With CLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 24, 2020

Expires: April 23, 2021

Faculty

cover img faculity

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

cover img faculity

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

cover img faculity

Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology
Consultant
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics AbbVie